CUHK Launches World's First AI-Powered Gut Microbiome Test for Early Autism Detection
核心洞察
The Chinese University of Hong Kong and spin-off MicroSigX (搜索) have launched the world's first AI-powered multikingdom microbial biomarkers technology for autism spectrum disorder (搜索) risk detection in children.
The non-invasive test analyzes gut microbiome (搜索) samples to generate ASD (搜索) risk scores with over 95% negative predictive value, helping exclude low-risk cases and reduce parental anxiety.
The technology received FDA Breakthrough Device Designation in July 2024 and will offer 200 free tests to eligible preschool children starting January 2026.
The Chinese University of Hong Kong's Faculty of Medicine has officially launched the world's first AI-powered multikingdom microbial biomarkers technology for detecting autism spectrum disorder (搜索) risk in children. The breakthrough diagnostic tool, developed in collaboration with CUHK (搜索) spin-off MicroSigX Biotech Diagnostic Limited (搜索), received FDA Breakthrough Device Designation in July 2024, marking a significant milestone in early autism identification.
Revolutionary Non-Invasive Diagnostic Approach
The MSX Metagenie (搜索)® technology addresses a critical unmet clinical need in autism diagnosis. With global ASD (搜索) incidence steadily rising—new cases quadrupling compared to two decades ago—families often face prolonged uncertainty while waiting for specialist evaluations. In Hong Kong alone, over 22,000 children have been diagnosed with ASD, showing an upward trend in recent years.
Professor Siew Ng, Associate Dean (Research) at CU Medicine (搜索) and Croucher Professor of Medical Sciences, explained the technology's innovative approach: "We can measure microbial signatures from a small fecal sample, analysing bacteria, archaea, fungi, and viruses, along with their genes and metabolic pathways. This data is processed through a validated AI model to generate an ASD (搜索) risk score."
The development stems from groundbreaking research published in Nature Microbiology in 2024, which identified changes in four kingdoms of microbial species in the gut microbiome (搜索) of children with ASD (搜索).
Clinical Performance and Impact
The diagnostic test demonstrates exceptional clinical performance with over 95% negative predictive value for autism exclusion. Professor Sandra Chan from the Department of Psychiatry at CU Medicine (搜索) emphasized the technology's clinical utility: "The test has shown a more than 95% negative predictive value, effectively ruling out autism. This provides reliable information to help exclude low-risk cases, enabling better allocation of medical and social resources to high-risk groups while alleviating parental concerns."
This high negative predictive value enables effective risk stratification, helping healthcare systems prioritize resources for high-risk children while reducing unnecessary anxiety for families of low-risk children.
Pilot Initiative and Community Impact
Beginning January 2026, CU Medicine (搜索) and MicroSigX (搜索) will launch a pilot initiative offering free MSX Metagenie (搜索)® tests to 200 eligible preschool children aged 18 months to 4 years with suspected ASD (搜索) symptoms but no formal diagnosis. The program will collaborate with non-profit organizations and adopt a "holistic care" model, partnering with NGOs and neurodevelopmental experts to create cross-disciplinary support teams.
Professor Sun Dong, Secretary for Innovation, Technology and Industry of the HKSAR, highlighted the initiative's broader significance: "Today's pilot initiative not only marks a milestone in commercialisation of research and development outcomes, but also benefits the underprivileged local families by providing free tests to those in need with the assistance of non-governmental organisations."
Comprehensive Care Framework
CU Medicine (搜索) plans to establish an "Advancement Centre for Autism" to develop training programs for community healthcare professionals. The center aims to promote practical knowledge on autism assessment while integrating medical, social, family, and educational support systems.
MicroSigX (搜索), supported by the Hong Kong government's RAISe+ Scheme, is expanding into global markets with plans to seek registration in Chinese Mainland and the United States. Professor Francis KL Chan, Choh-Ming Li Professor of Medicine and Therapeutics from CU Medicine (搜索), stated: "Our groundbreaking technology shows how government, industry, academia, and the research community can tackle healthcare challenges through innovation."
The initiative represents a comprehensive approach to autism care, with MicroSigX (搜索) envisioning the development of a "Centre of Excellence" for ASD (搜索) that will benefit Hong Kong, the Greater Bay Area, and beyond through multidisciplinary collaboration across healthcare, public, private, finance, and insurance sectors.